Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.

The respiratory medical community is moving toward shared decision-making in self-managing chronic respiratory disease, but ...

After 1 year of biologic therapy, admissions requiring noninvasive ventilation among patients with COPD and type 2 ...

Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...

Merck & Co. Inc. (NYSE:MRK) is one of the best growth stocks to buy now. On October 7, Merck & Co. announced the completion ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding ...

That observation encapsulates why chronic disease management as we practise it today is reactive rather than predictive.

Phyxiom, developer of a platform aiming to enhance asthma and chronic obstructive pulmonary disease (COPD) management, has announced its official launch. Dublin, Ireland-based Phyxiom launches as a ...

Senotherapeutics may offer a targeted treatment approach to cellular senescence in chronic obstructive pulmonary disease, according to a recent review. Senotherapeutics may offer a targeted treatment ...

Advances made in digital health in recent years have the potential to improve the care of patients living with chronic obstructive pulmonary disease (COPD) for whom substantial disability still exists ...